Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

S-phase synchronized CHO cells show elevated transfection efficiency and expression using CaPi.

Grosjean F, Batard P, Jordan M, Wurm FM.

Cytotechnology. 2002 Jan;38(1-3):57-62. doi: 10.1023/A:1021197830091.

2.

Dextramers: new generation of fluorescent MHC class I/peptide multimers for visualization of antigen-specific CD8+ T cells.

Batard P, Peterson DA, Devêvre E, Guillaume P, Cerottini JC, Rimoldi D, Speiser DE, Winther L, Romero P.

J Immunol Methods. 2006 Mar 20;310(1-2):136-48. Epub 2006 Feb 17.

PMID:
16516226
3.

Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.

Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2004 May 19;4:4.

4.

Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

Zippelius A, Batard P, Rubio-Godoy V, Bioley G, Liénard D, Lejeune F, Rimoldi D, Guillaume P, Meidenbauer N, Mackensen A, Rufer N, Lubenow N, Speiser D, Cerottini JC, Romero P, Pittet MJ.

Cancer Res. 2004 Apr 15;64(8):2865-73.

5.
6.

Human thymus exports naive CD8 T cells that can home to nonlymphoid tissues.

Zippelius A, Bioley G, Le Gal FA, Rufer N, Brandes M, Batard P, De Smedt M, Plum J, Speiser DE, Cerottini JC, Dietrich PY, Romero P, Pittet MJ.

J Immunol. 2004 Mar 1;172(5):2773-7.

7.

Disease-driven T cell activation predicts immune responses to vaccination against melanoma.

Speiser DE, Rimoldi D, Batard P, Liénard D, Lejeune F, Cerottini JC, Romero P.

Cancer Immun. 2003 Sep 9;3:12.

8.

Alpha 3 domain mutants of peptide/MHC class I multimers allow the selective isolation of high avidity tumor-reactive CD8 T cells.

Pittet MJ, Rubio-Godoy V, Bioley G, Guillaume P, Batard P, Speiser D, Luescher I, Cerottini JC, Romero P, Zippelius A.

J Immunol. 2003 Aug 15;171(4):1844-9.

9.

Ex vivo characterization of human CD8+ T subsets with distinct replicative history and partial effector functions.

Rufer N, Zippelius A, Batard P, Pittet MJ, Kurth I, Corthesy P, Cerottini JC, Leyvraz S, Roosnek E, Nabholz M, Romero P.

Blood. 2003 Sep 1;102(5):1779-87. Epub 2003 May 15.

PMID:
12750165
10.

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Liénard D, Rufer N, Dietrich PY, Speiser DE, Cerottini JC.

Immunol Rev. 2002 Oct;188:81-96. Review.

PMID:
12445283
11.

Use of phycoerythrin and allophycocyanin for fluorescence resonance energy transfer analyzed by flow cytometry: advantages and limitations.

Batard P, Szollosi J, Luescher I, Cerottini JC, MacDonald R, Romero P.

Cytometry. 2002 Jun 1;48(2):97-105.

12.

Specific dose-response effects of TGF-beta1 on developmentally distinct hematopoietic stem/progenitor cells from human umbilical cord blood.

Fortunel N, Hatzfeld J, Aoustin L, Batard P, Ducos K, Monier MN, Charpentier A, Hatzfeld A.

Hematol J. 2000;1(2):126-35. Erratum in: Hematol J 2000;1(3):218.

PMID:
11920180
13.

In vivo activation of melanoma-specific CD8(+) T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus-specific T cells.

Speiser DE, Liénard D, Pittet MJ, Batard P, Rimoldi D, Guillaume P, Cerottini JC, Romero P.

Eur J Immunol. 2002 Mar;32(3):731-41.

14.

Thymic selection generates a large T cell pool recognizing a self-peptide in humans.

Zippelius A, Pittet MJ, Batard P, Rufer N, de Smedt M, Guillaume P, Ellefsen K, Valmori D, Liénard D, Plum J, MacDonald HR, Speiser DE, Cerottini JC, Romero P.

J Exp Med. 2002 Feb 18;195(4):485-94.

15.

Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.

Dutoit V, Rubio-Godoy V, Doucey MA, Batard P, Liénard D, Rimoldi D, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D.

J Immunol. 2002 Feb 1;168(3):1167-71.

16.

Fluorescent proteins in animal cells for process development: optimization of sodium butyrate treatment as an example.

Hunt L, Batard P, Jordan M, Wurm FM.

Biotechnol Bioeng. 2002 Mar 5;77(5):528-37.

PMID:
11788951
17.

The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alpha beta T cells.

Speiser DE, Colonna M, Ayyoub M, Cella M, Pittet MJ, Batard P, Valmori D, Guillaume P, Liénard D, Cerottini JC, Romero P.

J Immunol. 2001 Dec 1;167(11):6165-70.

18.

Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.

Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D.

Cancer Res. 2001 Aug 1;61(15):5850-6.

19.

Transfer of high copy number plasmid into mammalian cells by calcium phosphate transfection.

Batard P, Jordan M, Wurm F.

Gene. 2001 May 30;270(1-2):61-8.

PMID:
11404003
20.

Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-beta type II receptor in a short-term in vitro assay.

Fortunel N, Hatzfeld J, Kisselev S, Monier MN, Ducos K, Cardoso A, Batard P, Hatzfeld A.

Stem Cells. 2000;18(2):102-11.

21.

TGF-(beta)1 maintains hematopoietic immaturity by a reversible negative control of cell cycle and induces CD34 antigen up-modulation.

Batard P, Monier MN, Fortunel N, Ducos K, Sansilvestri-Morel P, Phan T, Hatzfeld A, Hatzfeld JA.

J Cell Sci. 2000 Feb;113 ( Pt 3):383-90.

22.

High proliferative potential-quiescent cells: a working model to study primitive quiescent hematopoietic cells.

Fortunel N, Batard P, Hatzfeld A, Monier MN, Panterne B, Lebkowski J, Hatzfeld J.

J Cell Sci. 1998 Jul;111 ( Pt 13):1867-75.

23.

IL-3, GM-CSF and CSF-1 modulate c-fms mRNA more rapidly in human early monocytic progenitors than in mature or transformed monocytic cells.

Panterne B, Hatzfeld A, Sansilvestri P, Cardoso A, Monier MN, Batard P, Hatzfeld J.

J Cell Sci. 1996 Jul;109 ( Pt 7):1795-801.

24.

The Tie receptor tyrosine kinase is expressed by human hematopoietic progenitor cells and by a subset of megakaryocytic cells.

Batard P, Sansilvestri P, Scheinecker C, Knapp W, Debili N, Vainchenker W, Bühring HJ, Monier MN, Kukk E, Partanen J, Matikainen MT, Alitalo R, Hatzfeld J, Alitalo K.

Blood. 1996 Mar 15;87(6):2212-20.

PMID:
8630381
25.

Increased stable retroviral gene transfer in early hematopoietic progenitors released from quiescence.

Hatzfeld A, Batard P, Panterne B, Taieb F, Hatzfeld J.

Hum Gene Ther. 1996 Jan 20;7(2):207-13.

PMID:
8788171
26.

Early CD34high cells can be separated into KIThigh cells in which transforming growth factor-beta (TGF-beta) downmodulates c-kit and KITlow cells in which anti-TGF-beta upmodulates c-kit.

Sansilvestri P, Cardoso AA, Batard P, Panterne B, Hatzfeld A, Lim B, Lévesque JP, Monier MN, Hatzfeld J.

Blood. 1995 Sep 1;86(5):1729-35.

PMID:
7544639
27.

An improved panning technique for the selection of CD34+ human bone marrow hematopoietic cells with high recovery of early progenitors.

Cardoso AA, Watt SM, Batard P, Li ML, Hatzfeld A, Genevier H, Hatzfeld J.

Exp Hematol. 1995 May;23(5):407-12.

PMID:
7536682
28.

Purification and release from quiescence of umbilical cord blood early progenitors reveal their potential to engraft adults.

Hatzfeld J, Batard P, Cardoso AA, Li ML, Panterne B, Sansilvestri P, Ginsbourg M, Levesque JP, Hatzfeld A.

Blood Cells. 1994;20(2-3):430-4; discussion 434-5.

PMID:
7538349
29.

Release from quiescence of CD34+ CD38- human umbilical cord blood cells reveals their potentiality to engraft adults.

Cardoso AA, Li ML, Batard P, Hatzfeld A, Brown EL, Levesque JP, Sookdeo H, Panterne B, Sansilvestri P, Clark SC, et al.

Proc Natl Acad Sci U S A. 1993 Sep 15;90(18):8707-11.

30.

[Positive and negative controls on hematopoietic progenitor development: models and facts].

Panterne B, Hatzfeld A, Zhou YQ, Li ML, Sansilvestri P, Cardoso A, Lévesque JP, Ginsbourg M, Batard P, Kiselev S, et al.

Nouv Rev Fr Hematol. 1993 Jun;35(3):281-3. French.

PMID:
8337145
31.

Co-stimulatory effects of steel factor, the c-kit ligand, on purified human hematopoietic progenitors in low cell density culture.

Li ML, Cardoso A, Sansilvestri P, Hatzfeld A, Kisselev S, Batard P, Levesque JP, Hatzfeld J.

Nouv Rev Fr Hematol. 1993 Feb;35(1):81-6.

PMID:
7685520
32.

Human umbilical cord blood CD34+ cell purification with high yield of early progenitors.

Cardoso AA, Li ML, Batard P, Sansilvestri P, Hatzfeld A, Levesque JP, Lebkowski JS, Hatzfeld J.

J Hematother. 1993 Summer;2(2):275-9.

PMID:
7522882

Supplemental Content

Loading ...
Support Center